摘要 : Purpose: Lenvatinib is an oral multi-targeted tyrosine kinase inhibitor of VEGFR1-3, FGFR1-4, PDGFRβ, RET, and KIT. Everolimus is an oral mammalian target of rapamycin inhibitor approved for advanced renal cell carcinoma (RCC). Th... 展开
作者 | Michaelson~M.D. Molina~A.M. Hutson~T.E. Larkin~J. Gold~A.M. Wood~K. Carter~D. Motzer~R. |
---|---|
作者单位 | |
期刊名称 | 《Cancer Chemotherapy and Pharmacology》 |
总页数 | 9 |
语种/中图分类号 | 英语 / R96 |
关键词 | Antitumor Everolimus Lenvatinib Metastatic renal cell carcinoma mTOR VEGF |
馆藏号 | N2007EPST0000196 |